New drug PYX-201 targets Hard-to-Treat cancers in early trial

NCT ID NCT05720117

Recruiting now Disease control Sponsor: Pyxis Oncology, Inc Source: ClinicalTrials.gov ↗

First seen Mar 23, 2026 · Last updated May 12, 2026 · Updated 9 times

Summary

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain types of breast cancer, head and neck cancer, or other solid tumors will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cliniques Universitaires Saint-Luc
RECRUITING

Brussels, Brussels Capital, 1200, Belgium
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
HonorHealth Research Institute
RECRUITING

Scottsdale, Arizona, 85258, United States
Hospital Clínico Universitario de Valencia
RECRUITING

Valencia, València, 46010, Spain
Hospital Universitari Vall d'Hebrón
RECRUITING

Barcelona, Barcelona, 08035, Spain
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, Madrid, 28041, Spain
Hospital Universitario HM Sanchinarro
RECRUITING

Madrid, Madrid, 28050, Spain
Institut Jules Bordet
RECRUITING

Brussels, Brussels Capital, 1070, Belgium
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
NEXT Dallas
RECRUITING

Dallas, Texas, 75231, United States
NEXT San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Rhode Island Hospital
RECRUITING

Providence, Rhode Island, 02903, United States
Ronald Reagan UCLA Medical Center
RECRUITING

Los Angeles, California, 90095, United States
SCRI - Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
SCRI - HealthOne Denver
RECRUITING

Denver, Colorado, 80218, United States
START Madrid - Hospital Universitario Fundación Jiménez Díaz
RECRUITING

Madrid, Madrid, 28040, Spain
Sarah Cannon Research Institute London
ACTIVE_NOT_RECRUITING

London, England, W1G 6AD, United Kingdom
The Royal Marsden Hospital
ACTIVE_NOT_RECRUITING

London, England, SW3 6JJ, United Kingdom
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Universitair Ziekenhuis Antwerpen
RECRUITING

Edegem, Edegem, 2650, Belgium
Universitair Ziekenhuis Gent
RECRUITING

Ghent, Gent, 9000, Belgium
University College Hospital
ACTIVE_NOT_RECRUITING

London, England, NW1 2PG, United Kingdom
University of Chicago Medicine
RECRUITING

Chicago, Illinois, 60637, United States
University of Cincinnati Medical Center
RECRUITING

Cincinnati, Ohio, 45219, United States
University of Pennsylvania, Abramson Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19106, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110-1010, United States
Winship Cancer Institute, Emory University
RECRUITING

Atlanta, Georgia, 30308, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR SOLID TUMOR